Authors
Noémie S Minczeles, Eelke M Bos, Reinoud C de Leeuw, Johan M Kros, Mark W Konijnenberg, Jacoline EC Bromberg, Wouter W de Herder, Clemens MF Dirven, Johannes Hofland, Tessa Brabander
Publication date
2023/3
Journal
European Journal of Nuclear Medicine and Molecular Imaging
Volume
50
Issue
4
Pages
1195-1204
Publisher
Springer Berlin Heidelberg
Description
Purpose
There is no evidence-based systemic therapy for patients with progressive meningiomas for whom surgery or external radiotherapy is no longer an option. In this study, the efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with progressive, treatment-refractory meningiomas were evaluated.
Methods
Retrospective analysis of all meningioma patients treated with [177Lu]Lu-DOTA-TATE from 2000 to 2020 in our centre. Primary outcomes were response according to RANO bidimensional and volumetric criteria and progression-free survival (PFS). Overall survival (OS) and tumour growth rate (TGR) were secondary endpoints. TGR was calculated as the percentage change in surface or volume per month.
Results
Fifteen meningioma patients received [177Lu]Lu-DOTA-TATE (7.5–29.6 GBq). Prior to PRRT, all patients had received external radiotherapy, and 14 patients had undergone …
Total citations
Scholar articles
NS Minczeles, EM Bos, RC de Leeuw, JM Kros… - European Journal of Nuclear Medicine and Molecular …, 2023